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Spinal muscular atrophy (SMA) is a hereditary childhood disease that causes paralysis
and progressive degeneration of skeletal muscles and spinal motor neurons. SMA is
associated with reduced levels of full-length Survival of Motor Neuron (SMN) protein,
due to mutations in the Survival of Motor Neuron 1 gene. Nowadays there are no
effective therapies available to treat patients with SMA, so our aim was to test whether
the non-toxic carboxy-terminal fragment of tetanus toxin heavy chain (TTC), which
exhibits neurotrophic properties, might have a therapeutic role or benefit in SMA. In
this manuscript, we have demonstrated that TTC enhance the SMN expression in
motor neurons “in vitro” and evaluated the effect of intramuscular injection of TTC-
encoding plasmid in the spinal cord and the skeletal muscle of SMNdelta7 mice. For
this purpose, we studied the weight and the survival time, as well as, the survival and
cell death pathways and muscular atrophy. Our results showed that TTC treatment
reduced the expression of autophagy markers (Becn1, Atg5, Lc3, and p62) and pro-
apoptotic genes such as Bax and Casp3 in spinal cord. In skeletal muscle, TTC was
able to downregulate the expression of the main marker of autophagy, Lc3, to wild-type
levels and the expression of the apoptosis effector protein, Casp3. Regarding the genes
related to muscular atrophy (Ankrd1, Calm1, Col19a1, Fbox32, Mt2, Myod1, NogoA,
Pax7, Rrad, and Sln), TTC suggest a compensatory effect for muscle damage response,
diminished oxidative stress and modulated calcium homeostasis. These preliminary
findings suggest the need for further experiments to depth study the effect of TTC in
SMA disease.
Keywords: spinal muscular atrophy, c-terminal fragment of the tetanus toxin, muscle, spinal cord, autophagy,
apoptosis, muscular atrophy
Abbreviations: SEM: standard error of the mean; SMA: spinal muscular atrophy; SMN: survival motor neuron; TTC:
C-terminal fragment of the tetanus toxin; WT: wild type.
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INTRODUCTION
Motor neuron diseases, a group of heterogeneous neurological
disorders such as Amyotrophic Lateral Sclerosis (ALS) and
Spinal Muscular Atrophy (SMA), are characterized by varying
degrees of motor neuron degeneration. In particular, SMA is an
autosomal recessive motor neuron disease and the first genetic
cause of infant mortality, characterized by the degeneration
of motor neurons in the anterior horn of the spinal cord,
resulting in muscular atrophy and weakness. SMA patients have
a homozygous loss of the survival motor neuron 1 (SMN1)
gene, but retain one or more copies of a nearly identical
homolog, SMN2. Therefore this disease is the result of insufficient
amounts of SMN protein and its levels are generally inversely
correlated with the severity of the disease, hence making SMN2
copy number the predominant modifier of the neuromuscular
phenotype (Monani and De Vivo, 2014). In SMA pathology, the
most striking component is the loss of alpha motor neurons
in the ventral horn of the spinal cord, resulting in progressive
paralysis and eventually premature death. Despite the time that
has elapsed since the SMA genes were identified, the currently
available treatments for patients affected by the disease are
palliative, based on symptomatic treatments and supportive care
(Monani and De Vivo, 2014). Nowadays, the most interesting
therapeutic strategies are represented by molecular, gene and
stem cell-mediated approaches which are focused on activating
SMN2 expression, modulating splicing of SMN2 or replacing
SMN1 (Zanetta et al., 2014; d’Ydewalle and Sumner, 2015).
A promising therapeutic approach could be the non-viral
gene therapy based on the use of atoxic C-terminal fragment
of the tetanus toxin (TTC). Tetanus neurotoxin is a protein
produced by Clostridium tetani that cause tetanus, a fatal
condition characterized by painful and uncontrolled muscle
contractions (Farrar et al., 2000). The toxin is synthesized as
a single polypeptide and is posts-translationally modified to
produce light and heavy chains linked by disulfide bonds (Turton
et al., 2002). The catalytic domain of the toxin resides in the light
chain, while the translocation and receptor-binding domains are
present in the heavy chain (Montal, 2010). Moreover, the heavy
chain consists of two non-toxic fragments, the N-terminal or
translocation domain and the C-terminal or receptor-binding
domain (Chen et al., 2012). The atoxic TTC heavy chain
(hereafter called TTC) can be retrogradely transported to the
central nervous system and may be linked to different molecules
without apparent loss of biological activity. The ganglioside-
binding properties of fragment C have demonstrated that the
presence of polysialic acids within the gangliosides, such as
GD1b (disialic acid residues attached to the internal galactose
residue) and GT1b (disialic acid residues attached to the
terminal galactose residue) in cell membranes are neccesary
to enable the tetanus-toxin internalization and therefore the
TTC internalization in neurons. Additionally, the neurotrophin
receptor p75NTR and TrkB is also essential in the retrograde
pathway of TTC, sharing with NGF and BDNF the same
retrograde transport organelles (Calvo et al., 2012b). These
features allow the use of TTC as a valuable biological carrier
of therapeutic molecules such as reporter genes or neurotrophic
factors to ameliorate the disease advances of neurodegenerative
disorders (Toivonen et al., 2010). In ALS, the delivery of
glial cell-derived neurotrophic factor (GDNF) or brain derived
neurotrophic factor (BDNF) to the spinal cord is improved by
conjugation with TTC after intramuscular administration (Ciriza
et al., 2008; Calvo et al., 2011). In SMA, one therapeutic strategy
could be based on increasing the levels of neuronal SMN, for this
reason, the genetic fusion of SMN and TTC was applied to deliver
exogenous SMN to the cytosolic compartment of motor neurons
(Francis et al., 2004). Interestingly, in vitro and in vivo studies
have also shown that TTC itself may well harbor neuroprotective
properties (Toivonen et al., 2010; Calvo et al., 2012b). In this
way, in the mouse model SOD1G93A of ALS, the intramuscular
injection of naked DNA encoding for TTC ameliorated the
decline of hind limb muscle innervation, significantly delayed
the onset of symptoms and functional deficits, improved spinal
motor neuron survival and prolonged lifespan (Moreno-Igoa
et al., 2010).
In the light of these preliminary results, the aim of the
present study was to evaluate the possible therapeutic effect of
intramuscular delivery of a TTC-encoding plasmid in the spinal
cord and the skeletal muscle tissues of an intermediate mouse
model of SMA, the SMNdelta7 mouse. In order to evaluate
the neuroprotective effects under TTC treatment, we firstly
registered the weight and the survival time, and the survival
rate to further analyze the expression of several genes related
to neurodegenerative process, in particular, autophagy, apoptosis
and muscle atrophy.
MATERIALS AND METHODS
The care and use of animals were performed accordingly with the
Spanish Policy for Animal Protection RD53/2013, which meets
the European Union Directive 2010/63/UE on the protection
of animals used for experimental and other scientific purposes.
The in-house Ethic Committees for Animal Experiments of
the Universidad de Zaragoza and Universitat Autònoma de
Barcelona approved all of the experimental procedures.
Spinal Cord Organotypic Culture and
TTC Supplementation
Spinal cord organotypic cultures were obtained from lumbar
spinal cords of 8-day-old Sprague-Dawley rat pups as previously
described (Herrando-Grabulosa et al., 2013). Cultures were let to
stabilize for 1 week, and after this point the medium was changed
twice per week until 15 days in vitro (DIV).
TTC protein used in spinal cord organotypic culture
treatments were purificated as previously described (Herrando-
Grabulosa et al., 2013). TTC protein was added to the warm-fresh
culture medium at a concentration of 10 nM.
Immunoblotting
Spinal cord slices were collected in lysis buffer, homogenated, and
quantified by BCA assay. Equal amounts of protein (20 µg/well)
were resolved in SDS-PAGE and transferred to nitrocellulose
membrane. Membranes were blocked with 6% non-fat dry milk
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in phosphate buffered saline (PBS) for 1 h at room temperature
(RT) and incubated overnight with the corresponding primary
antibody diluted in blocking buffer (SMN, 1:500, BD Biosciences
and anti-β-tubulin, Becton-Dickinson). After several washes,
membranes were incubated for 1 h with an appropriate secondary
antibody. Blots were developed using a chemoluminiscent mix
and exposed to enzymatic chemoluminiscence (ECL) films
(Amersham Pharmacia Biotech). Densitometry was carried out
using ImageJ software.
Immunofluorescence
For organotypic cultures, spinal cord slices were fixed with 4%
paraformaldehyde (PFA) at RT for 1 h. Slices were then washed
twice with PBS for 15 min, blocked with 5% normal horse
serum and 0.2% Triton-X-100 in PBS, and incubated overnight
at 4◦C with antibody against mouse anti-neurofilament heavy-
chain (NF-H) (SMI-32; 1:1000, Sternberger Monoclonals Inc.)
and rabbit anti-survival motor neuron (SMN; 1:50, Santa Cruz).
Slices were then thoroughly washed in PBS with 0.2% Tween-
20 and incubated with appropriate secondary antibody Alexa
Fluor R©555 goat anti-rabbit IgG (1:500) and Alexa Fluor R©488
goat anti-mouse IgG (1: 1000) diluted in blocking buffer
for 1 h at RT. Then, slices were incubated for 20 min
with 4′-6-Diamidino-2-phenylindole (DAPI). Finally, slices were
mounted in Superfrost R©Plus slides (Thermo Fisher Scientific)
with Fluoromount-G mounting medium (SouthernBiotech) and
fluorescence was visualized under epifluorescence microscope
(Nikon Eclipse 90i; Nikon Instruments Inc.) or Olympus
FluoViewTM FV1000). Motor neurons in the organotypic spinal
cord slices were identified by SMI-32 immunostaining on
the basis of their morphology and size (>20 µm) and their
localization in the ventral horn. A minimum of 15 sections were
used for MN counting for each experimental condition.
In case of SMA mice, animals were perfused transcardially
with cold 4% PFA in PBS. Spinal cords were dissected, post-
fixed in PFA for 24 h, and transferred to 30% sucrose in
PBS for at least 48 h at 4◦C. Sample tissues were embedded
in OCT (Tissue-Tek, Sakura Finetek) and frozen in liquid
nitrogen-cooled 2-methylbutane. Transverse sections of spinal
cord (10 µm) were cut with using a cryostat (CM1510S Leica
Microsystems). Tissue sections were re-fixed on ice with formalin
solution 10% (HT5014, Sigma) for 10 min, permeabilized with
0.1% Triton X-100 and 0.1% sodium citrate in PBS for 10 min
at RT, and blocked with 10% goat serum and 1% BSA in PBS
for 30 min at RT. After washes, sections were incubated with
LC3 primary antibody (1:200; PD014, MBL) over night at 4◦C,
and subsequently incubated with Alexa Fluor 546 goat anti-rabbit
IgG (Invitrogen) for 1 h at RT. Nuclear staining (in blue) was
performed using a mounting medium with DAPI (Vectashield,
H-1200, Vector Laboratories) and visualized on an Olympus
IX81 fluorescence microscope.
SMA Mice
Moderate Type II SMA mice FVB.Cg-Tg(SMN2∗delta7)
4299Ahmb Tg(SMN2)89Ahmb Smn1tm1Msd/J were kindly
provided by Dra. Lucía Tabares (Universidad de Sevilla).
Transgenic Smn+/−;SMN2;SMN17 mice were maintained as
heterozygous breeding pairs in the Servicio General de Apoyo a
la Investigación-SAI of the Universidad de Zaragoza.
This mouse model at birth is noticeably smaller than normal
littermates. Signs of muscle weakness appear progressively after
day 5 and the mouse displays an abnormal gait, shakiness in the
hind limbs and a tendency to fall over with a lifespan of 13 days
(Le et al., 2005). Body weight and survival measures were taken
daily in the morning. To evaluate these parameters, we produced
9 l with 71 pups, 5 lwere injected with pCMV–TTC plasmid (TTC
treatment) and 4 with pCMV plasmid (untreated). In relation
of the 71 pups, 21 were SMA mice (10 treated with TTC and
11 untreated), 35 were heterozygous mice (25 treated with TTC
and 10 untreated) and 15 were WT (7 treated with TTC and 8
untreated).
To study the gene expression by real-time PCR, we produced
9 l with 81 pups, 5 lwere injected with pCMV-TTC plasmid
and 4 with pCMV plasmid. In relation of the 81 pups,
10 were SMA mice (5 treated with TTC and 5 untreated),
48 were heterozygous mice (25 treated with TTC and 23
untreated) and 23 were WT (14 treated with TTC and 9
untreated).
Finally, in relation to immunofluorescence assay, we produced
7 l with 43 pups, 5 l were injected with pCMV-TTC plasmid and
2 with pCMV plasmid. In relation of the 43 pups, 6 were SMA
mice (3 treated with TTC and 3 untreated), 21 were heterozygous
mice (12 treated with TTC and 9 untreated), and 23 were WT (10
treated with TTC and 6 untreated).
Plasmid Purification and Intramuscular
Injection
The TTC gene used in mice treatments was constructed in
the pcDNA3.1 eukaryotic expression plasmid under the control
of the cytomegalovirus (CMV) immediate-early promoter.
pCMV:TTC was obtained by cloning a BamHI/NotI TTC
fragment from the pGex:TTC vector (Coen et al., 1997) into
pcDNA3.1 as previously described (Moreno-Igoa et al., 2010).
For the transformation assay, competent cells (Escherichia
coli DH5α bacteria) were used, and the constructed plasmids
were purified with QIAprep Spin Miniprep kit (QIAGEN).
The sequence of the purified plasmids (BigDye Terminator
v3.1 Cycle Sequencing kit, Applied Biosystems) was checked
to confirm that the cloned DNA fragments were correctly
inserted in the vectors. The recombinant plasmids were finally
expanded in DH5α bacteria and purified using the EndoFree
Plasmid Mega Kit (Qiagen). The recombinant plasmids were
subjected to 1% agarose gel in 1X Tris-boric-EDTA (TBE) to
yield fragments of the expected molecular weight. The quantity
of the obtained recombinant plasmids was measured using a
NanoDrop R© Spectrophotometer (ND-1000 V3.3.0).
At post-natal day 1 (P1) mice were immobilized via
cryoanesthesia and injected intramuscularly with 100µg of naked
DNA encoding for pCMV-TTC or non-coding pCMV plasmids
into the quadriceps femoris muscles (one injection with 50 µg per
muscle).
At P7 (early-symptomatic), the pups were lightly anesthetized
with isoflurane and were euthanized by rapid decapitation. The
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skeletal muscle and spinal cord tissues were harvested, snap-
frozen in liquid nitrogen, and then stored at −80◦C for RNA
extraction.
Quantitative PCR
Spinal cord and muscle tissue were pulverized in liquid
nitrogen with a cell crusher. For RNA extraction, powdered
samples were resuspended with Trizol Reagent (Invitrogen).
RNA extracted was treated to eliminate genomic DNA using the
Turbo DNA-freeTM kit (Ambion) and the reverse transcription
was carried out according to the SuperScriptTM First-Strand
Synthesis System kit (Invitrogen). Gene expression was assayed
by real-time PCR in a StepOneTM Real-Time PCR System
(Applied Biosystems). Primer and probe mixtures for each gene
of interest were supplied by Applied Biosystems (Table 1).
Two endogenous genes (Gapdh and β-actin) were used for
normalization of the data. All reactions were performed in
triplicate and all reaction efficiencies of the primer/probe sets
were close to 100%. Target gene expression was normalized
using the geometric mean of these two housekeeping genes
and relative gene expression was determined using the 2−11CT
method.
Statistical Analysis
Statistical significance was determined by one-way ANOVA
followed by Bonferroni’s post-hoc test. Survival data was analyzed
using the Kaplan-Meir test. All of the values were expressed
as means and error bars represent standard error of the mean
(mean ± SEM). The statistical significance threshold was set at
p< 0.05.
RESULTS
TTC Treatment Increase SMN Expression
in Motor Neurons
Prior to the in vivo assays, the effects of TTC on SMN expression
and motor neuron survival were studied in vitro. In spinal
cord organotypic cultures, TTC protein enhanced levels of SMN
and also significantly increased the number of motor neurons
(Figures 1A,B). This effect was more evident than the observed
in the case of NGF supplementation. These results suggested
that TTC achieve a neuroprotective effect in motor neurons.
Moreover, immunoblotting quantification of SMN showed that
its expression was increased along the days of culture and reached
the highest level at 15DIV (Figure 1C).
The next step and prior to performing the assay in our severe
mice model of SMA, the non-viral gene therapy with pCMV-TTC
was assessed in vivo in a mouse model of motor neuron disease
(Supplementary Material S1). The results obtained showed that,
10 days after inoculation, TTC treatment significantly increased
the levels of the SMN gene in muscle and spinal cord tissues in
this animal model.
Improvement of the Autophagy and
Apoptosis Markers Under TTC Treatment
mRNA expression levels of the well-known markers of autophagy
(Becn1, Lc3, and p62) and apoptosis (Bax and Casp3) were
quantified by real-time PCR in spinal cord and skeletal muscle
samples of WT and SMA mice to evaluate the possible effect of
TTC treatment (Figure 2).
TABLE 1 | Taqman R© probe and primer mixtures used in gene expression assays.
Name Gen symbol Part number
Autophagy related 5 Atg5 Mm00504340_m1
Beclin 1, autophagy related Becn1 Mm00517174_m1
E2F transcription factor 1 E2f1 Mm00432939_m1
Microtubule-associated protein 1 light chain 3 alpha Map1lc3a (Lc3) Mm00458724_m1
Sequestosome 1 Sqstm1 (p62) Mm00448091_m1
BCL2-associated X protein Bax Mm00432050_m1
B cell leukemia/lymphoma 2 Bcl2 Mm00477631_m1
Caspase 1 Casp1 Mm00438023_m1
Caspase 3 Casp3 Mm01195085_m1
Ankyrin repeat domain 1 Ankrd1 Mm00496512_m1
Calmodulin 1 Calm Mm00486655_m1
Collagen type XIX alpha 1 Col19a1 Mm00483576_m1
F-box only protein 32 Fbxo32 Mm01207878_m1
Metallothionein 2 Mt2 Mm00809556_s1
Myogenic differentiation 1 Myod1 Mm00440387_m1
Paired box gene 7 Pax7 Mm00834079_m1
Ras-related associated with diabetes Rrad Mm00451053_m1
Sarcolipin Sln Mm00481536_m1
Survival motor neuron 1 (SMN 1) Smn1 Hs00165806_m1
Glyceraldehyde-3-phospate dehydrogenase Gapdh 4352932E
Actin, beta, cytoplasmic Actb (β-actin) 4352933E
Gapdh and Actb (β-actin) were used as housekeeping genes.
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FIGURE 1 | Enhanced levels of SMN protein after TTC treatment. (A) Representative images of the ventral horn hemisections immunolabeled against SMN
protein (red) and motor neuron marker SMI32 (green). Scale bar: 50 µm. (B) Bar graph showing the number of SMI-32 positive cells at the ventral horns with a
diameter >25 µm at 15DIV alone or under the treatment of NGF (50 ng/mL) or TTC (10 nM). Values are the mean ± SEM of at least 15 sections per treatment.
∗∗p < 0.01. (C) Evaluation by western blot analysis the levels of SMN protein under the treatment of NGF 50 ng/mL and TTC 10 nM along the progression of the
spinal cord organotypic culture (0, 7, 10, and 15DIV). All results were from at least two independent experiments. Equal amount of protein was added to each well.
In spinal cord tissue (Figure 2A), autophagy markers were
significantly upregulated in untreated SMA mice, suggesting
a potential autophagy activation due to the neurodegenerative
progression of the disease. Under TTC treatment, the mRNA
expression levels were significantly downregulated with respect
to untreated SMA mice, pointing out to an improvement
of autophagy markers, which tend to reach WT levels.
Furthermore, inmunofluorescence against LC3 demonstrated
that the over-expression of the LC3 transcripts was accompanied
to an activation of the expression of LC3 protein, suggesting
an activation of the autophagy process as a compensatory
mechanism (Figure 3). On the contrary, LC3 protein expression
was not observed in wild-type animals resembling what was
observed in the case of the mRNA transcript levels (Figure 3).
The expression levels of pro-apoptotic genes Bax and
Casp3 were significantly upregulated with respect to WT mice
suggesting an apoptosis enhancement in this tissue due to
the neurodegeneration. However, TTC treatment significantly
decreased the levels of both genes in relation to untreated SMA
mice, favoring an amelioration of apoptosis (Figure 2A).
In relation to the skeletal muscle tissue (Figure 2B), the
significant upregulated levels of Becn1, Lc3, and p62, in untreated
SMA mice were indicative of an autophagy activation, as it
was observed in spinal cord tissue. TTC treatment especially
improved Lc3 levels that reached the ones observed in WT
mice, suggesting a significant amelioration of autophagy process.
Furthermore, in SMA mice the levels of the pro-apoptotic gene
Bax were found significantly upregulated, while Casp3 levels
showed a tendency to be upregulated. Under TTC treatment, only
the Casp3 showed a significantly downregulation with respect to
untreated SMA mice, which could indicate a lack of apoptosis
activation.
Compensatory Response of TTC
Treatment for Muscular Atrophy in SMA
Mice
Spinal muscular atrophy and ALS, two lethal motor neuron
diseases, share affected target tissues such as the skeletal muscle.
In addition, muscle weakness and atrophy have been described in
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FIGURE 2 | Effect of TTC-encoding plasmid in autophagy and
apoptotic markers. Relative expression values of autophagy (Becn1, Lc3,
and p62) and apoptotic (Bax and Casp3) genes in WT mice (WT, black bars),
untreated SMA mice (SMA-C, dark gray bars) and SMA mice treated with TTC
(SMA-TTC, light gray bars) in spinal cord (A) and skeletal muscle (B). Each
data point represented the mean ± SEM, n = 5 animals per group. WT versus
SMA-C: ∗∗p < 0.01 and ∗∗∗p < 0.001. SMA-C versus SMA-TTC: #p < 0.05,
##p < 0.01 and ####p < 0.001.
SMA mouse models. Previous work from our group has described
a list of genetic biomarkers for ALS disease, some of which
were in close relation to muscle atrophy (Calvo et al., 2012a).
Consequently, transcriptional expression levels of seven genes
related to muscle atrophy (Ankrd1, Calm1, Col19a1, Mt2, Myod1,
NogoA, and Sln) (Calvo et al., 2012a) were tested in skeletal
muscle tissue from SMA mice (Figure 4).
Our results showed a significant upregulation of these genes
in untreated SMA mice, except for Myod1 that was significantly
downregulated. TTC treatment reduced significantly Ankrd1,
Calm1, Col19a1, Mt2, and NogoA levels, levels, and increased
Myod1 levels tending to reach WT ones, which could suggest
an improvement of the muscle atrophy under TTC treatment.
The significant upregulation of Sln1 levels under TTC treatment
could also indicate an improvement of the relaxation-contraction
cycles, favoring an amelioration of muscle atrophy (Casas et al.,
2013).
FIGURE 3 | Immunofluorescence staining for LC3 on spinal cord tissue
under TTC treatment. LC3 staining (red) was performed in WT mice and
SMA mice untreated and treated with TTC in spinal cord slices. DAPI staining
was also performed (blue). A merged image of the double staining is
presented. A representative image presents of three independent animals for
genotype and disease stages (40X).
Body Weight and Survival Rates Under
TTC Treatment
To evaluate the possible effect of TTC treatment in the SMA mice
phenotype, the body weight was registered daily along disease
progression. The results showed that the intramuscular injection
of TTC-encoding plasmid at P1 did not significantly affect the
body weight of WT or SMA mice during the first ten days of
life (Figure 5A). Nevertheless, the body weight of WT mice
significantly reached low levels from P12 until P16, while in
treated SMA mice, a significant decrement was only detected at
P11 and then a modest but no significant improvement in the
body weight was observed from P12 until P16, with respect to
untreated SMA mice.
Regarding the survival time, the data showed no significant
differences between WT or SMA mice after TTC injection
(Figure 5B). Albeit, it should be pointed out the high mortality
rate and the variable life expectancy of the SMA pups, and
therefore less severe animal model of the disease may allow a
long-lasting monitoring of TTC effects.
DISCUSSION
In recent years the neuroprotective effects of TTC have been
described in relation to the antiapoptotic and survival pathways,
suggesting a similar way of action as in the case of neurotrophins
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FIGURE 4 | Amelioration of genes related to muscular atrophy in SMA mice. Relative expression values of Myod1, Col19a1, Ankrd1, NogoA, Mt2, Sln, and
Calm1 in WT mice (WT, black bars), untreated SMA mice (SMA-C, dark gray bars) and SMA mice treated with TTC (SMA-TTC, light gray bars) in skeletal muscle
tissue. Each data point represented the mean ± SEM, n = 5 animals per group. WT versus SMA-C: ∗p < 0.05 and ∗∗∗p < 0.001. SMA-C versus SMA-TTC:
#p < 0.05 and ##p < 0.01.
in animal models of several neurodegenerative diseases (Chaib-
Oukadour et al., 2004). In this sense, it has been demonstrated in
neurons of mSOD1 mouse model of ALS that the neuroprotective
role of TTC was possibly due to its pro-survival and anti-
apoptotic properties (Moreno-Igoa et al., 2010; Herrando-
Grabulosa et al., 2013). A recent work in a mouse model
intermediate of SMA showed that this disease in skeletal muscle
emerges before pathology in spinal cord, including loss of motor
neurons. (Fayzullina and Martin, 2014). This cellular loss may
be mediated by apoptosis or autophagy, therefore therapeutic
strategies based on modulating these molecular mechanisms may
have potential beneficial effects in the SMA pathology or disease
progression. Moreover, the increment of SMN observed after
non-viral gene therapy treatment with pCMV-TTC could be
improved the beneficial effects related to TTC.
Autophagy has come to the forefront in motor neuron diseases
as a common molecular pathway altered in degenerating motor
neurons. The loss of critical genes involved in the execution of
the autophagy pathway in the central nervous system results
in profound severe neurodegenerative diseases (Komatsu et al.,
2006). Moreover, induction of autophagy has been reported in
numerous models of neurodegenerative diseases, and may be
a component of the cellular response to depleted SMN levels
(Custer and Androphy, 2014). At P7, the SMA pups were still
active and significantly smaller than their phenotypically normal
siblings (2.17 ± 0.28 vs. 4.18 ± 0.11), but signs of muscle
weakness were observed compared to their normal littermates.
Moreover, their relative mobility insured that they were still
gaining access to milk. The presence of milk in the stomach was
also visible through the skin, preventing any potential autophagy
induction due to poor nursing following the onset of major
motor coordination losses. In a severe model of SMA, in vitro
experiments showed a deregulated autophagy in spinal cord
motor neurons (Garcera et al., 2013). Moreover, LC3-II and
p62 protein levels were increased in lysates of spinal cord from
a severe mouse model of SMA indicating that autophagy is
dysregulated (Custer and Androphy, 2014). In accordance with
these results, our data revealed a significant increase in the
expression levels of all autophagy markers in spinal cord and
skeletal muscle tissues and therefore an activation of this process.
Although autophagy remained activated under TTC treatment in
SMA mice, the gene expression profile observed in treated SMA
mice tended to reach WT levels. In case of muscle, TTC treatment
decreased Lc3 expression to WT ones. This reduction of Lc3
levels suggested that TTC was able to reduce the pathological
autophagy until a constitutive autophagy, since Lc3 is considered
the main marker of autophagosomes.
In relation to apoptosis, the anti-apoptotic properties of
TTC were evidenced by in vitro studies in cultured neurons in
which TTC preserve mitochondrial function decreased nuclear
fragmentation and reduced activation of pro-Casp3 (Chaib-
Oukadour et al., 2004). Similarly, in vivo experiments in a
model of Parkinson’s (Mendieta et al., 2009) or ALS’s (Moreno-
Igoa et al., 2010) diseases, showed an anti-apoptotic effect of
TTC. In regard to apoptosis and neurodegenerative disorders,
a deregulation of this process is associated with a long list of
pathologies (Marino et al., 2014). In SMA disease, genetic studies
in mice (Kerr et al., 2000; Anderton et al., 2013) support a role
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FIGURE 5 | Phenotype and survival time of treated and untreated SMA
mice. (A) Weight curves of WT (circles) and SMA mice (squares) treat (closed
forms) and untreat (open forms) with TTC. All plots are shown as means of
weight at each day with error bars representing standard deviation. ∗p < 0.05.
(B) Kaplan–Meier survival analysis of WT and SMA mice with and without TTC
treatment.
for programmed neuronal death. Thus, in the central nervous
system of SMA mouse models, elevated levels of pro-apoptotic
genes and an enhancement of apoptosis have been observed
(Tsai et al., 2006). Moreover, a significant loss of large motor
neurons was observed in the spinal cord from SMNdelta7 mouse
at P7 (Baumer et al., 2009), and 2 days later this loss was over
50% (Edens et al., 2014). Furthermore, in the skeletal muscle of
severe SMA model mice, the presence of apoptotic cell death
signs was detected (Dachs et al., 2011). In connection with
these results, we observed that the pro-apoptotic gen Bax was
upregulated as well as the gen Casp3. Both genes encode for
the “executioner” proteins in apoptosis, suggesting that apoptosis
was activated. In relation to the skeletal muscle, a recent work
using the “Taiwanese” SMA mouse model, detected at birth
DNA damage that was getting worse until P6 when the muscle
exhibited cell death (Fayzullina and Martin, 2014). However,
in our SMA mice, the upregulation of Bax together with the
lack of upregulation of Casp3 suggested an absence of apoptotic
cell death in untreated SMA mice, which is in accordance with
the results obtained by Hayhurst and co-workers that revealed
normal proportion of apoptotic cells. After TTC treatment, the
expression levels of Bax and Casp3 in spinal cord and Casp3
in skeletal muscle were downregulated untreated SMA mice,
suggesting that TTC favored the normalization of the expression
levels of both genes and therefore played a relevant role in the
modulation of apoptosis in this animal model.
Although the importance of motor neuron pathology is well-
established in SMA, a cumulative body of work supports the
involvement of other cell types, including myocytes (Hamilton
and Gillingwater, 2013; Martinez-Hernandez et al., 2013; Iascone
et al., 2015). In SMA disease, muscle weakness and atrophy
are also principal pathological hallmarks. In this way, in mouse
models of the disease, several works reported an abnormal
skeletal muscle development (Boyer et al., 2013).
Consequently, our next step was the evaluation of the
expression of several genetic biomarkers related to muscular
atrophy, previously characterized by our group (Calvo
et al., 2012a). TTC administration significantly reduced the
transcriptional level of Myod1, an early marker of myogenesis
(Manzano et al., 2011), and Col19a1 which increasing levels
are related to the regenerative response to muscle damage
(Sumiyoshi et al., 2001), shifting their expression toward
the wild-type levels. Additionally, after TTC treatment the
expression levels of Ankrd1, a marker of muscle damage (Laure
et al., 2009), and Nogo A that accelerates the progressive
failure of motor neuron innervation (Pradat et al., 2007)
decreased to reach WT ones, suggesting that TTC could
ameliorate muscle atrophy. Finally, TTC treatment modified
the expression of Mt2, Calm1 and Sln genes which are also
associated to muscle atrophy (Hyldahl et al., 2010; Casas et al.,
2013).
In summary, non-viral gene therapy based on TTC improved
the expression levels of main genes related to autophagy and
apoptosis in SMA mice. In particular, in response to the
neurodegenerative progression in SMA mice, TTC treatment
modifies the expression of autophagy and apoptotic genes.
Additionally, TTC reduced the expression of autophagy markers
and pro-apoptotic genes in spinal cord while in skeletal muscle
TTC was able to downregulate the expression of the main
marker of autophagy (Lc3) to WT levels, as well as the
expression of the apoptosis effector, Casp3. Furthermore, in
the skeletal muscle tissue of treated SMA mice, TTC showed
a compensatory effect in the expression of genes involved
in muscle damage response, oxidative stress and calcium
homeostasis. These preliminary findings provide new insights
into the effect of TTC in the spinal cord and the skeletal
muscle tissues in SMA disease and suggest the need for
further experiments to accurate study the effect of TTC in this
disorder.
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